Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$1.01 - $1.82 $59,861 - $107,869
-59,269 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$1.39 - $2.21 $62,142 - $98,802
44,707 Added 307.01%
59,269 $108,000
Q1 2021

May 14, 2021

SELL
$1.27 - $3.42 $3,539 - $9,531
-2,787 Reduced 16.06%
14,562 $28,000
Q4 2020

Feb 12, 2021

SELL
$0.94 - $1.89 $675,456 - $1.36 Million
-718,571 Reduced 97.64%
17,349 $21,000
Q3 2020

Nov 13, 2020

BUY
$1.5 - $9.38 $919,968 - $5.75 Million
613,312 Added 500.22%
735,920 $1.32 Million
Q2 2020

Aug 12, 2020

BUY
$4.79 - $8.39 $281,982 - $493,910
58,869 Added 92.36%
122,608 $1.03 Million
Q1 2020

May 13, 2020

BUY
$3.44 - $7.21 $219,262 - $459,558
63,739 New
63,739 $334,000
Q4 2019

Feb 12, 2020

SELL
$4.29 - $5.64 $57,696 - $75,852
-13,449 Closed
0 $0
Q3 2019

Nov 12, 2019

SELL
$4.87 - $7.08 $11,059 - $16,078
-2,271 Reduced 14.45%
13,449 $65,000
Q2 2019

Aug 14, 2019

BUY
$6.6 - $7.8 $10,744 - $12,698
1,628 Added 11.55%
15,720 $109,000
Q1 2019

May 14, 2019

BUY
$5.76 - $8.95 $81,169 - $126,123
14,092 New
14,092 $99,000
Q4 2018

Feb 13, 2019

SELL
$5.26 - $7.97 $55,361 - $83,884
-10,525 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$4.65 - $7.95 $18,865 - $32,253
-4,057 Reduced 27.82%
10,525 $79,000
Q2 2018

Aug 14, 2018

SELL
$5.05 - $6.8 $54,933 - $73,970
-10,878 Reduced 42.73%
14,582 $73,000
Q1 2018

May 15, 2018

SELL
$5.6 - $9.25 $300,244 - $495,938
-53,615 Reduced 67.8%
25,460 $156,000
Q4 2017

Feb 14, 2018

BUY
$6.6 - $7.78 $330,541 - $389,637
50,082 Added 172.74%
79,075 $562,000
Q3 2017

Nov 14, 2017

BUY
$5.75 - $7.75 $166,709 - $224,695
28,993
28,993 $207,000

Others Institutions Holding CRBP

About Corbus Pharmaceuticals Holdings, Inc.


  • Ticker CRBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,268,000
  • Market Cap $1.27B
  • Description
  • Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...
More about CRBP
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.